SAN DIEGO 圣地亚哥, ，Oct. 14, 2026 2026年10月14日/PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical-stage biotech company focused on innovative drug discovery and development in immuno-oncology (IO), announced that the first patient has been dosed in the clinical study of spevatamig for the treatment of colorectal cancer (CRC). /美通社/ -- 专注于免疫肿瘤学（IO）领域创新药物发现与开发的临床阶段生物科技公司Phanes Therapeutics, Inc.（Phanes）宣布，其用于治疗结直肠癌（CRC）的spevatamig临床研究已完成首例患者给药。Spevatamig is a first-in-class native IgG-like bispecific antibody (bsAb) targeting claudin 18.2 and CD47. It was granted by the FDA orphan drug designation for the treatment of pancreatic cancer in 2022, Fast Track designation for the treatment of patients with metastatic claudin 18.2-positive pancreatic adenocarcinoma in 2024, and recently, Fast Track designation for the treatment of advanced and metastatic biliary tract carcinoma. Spevatamig 是一款首创的、具有天然 IgG 样结构的双特异性抗体（bsAb），靶向 Claudin 18.2 和 CD47。该药于 2022 年获得美国食品药品监督管理局（FDA）授予的用于治疗胰腺癌的孤儿药资格认定，于 2024 年获得用于治疗转移性 Claudin 18.2 阳性胰腺腺癌患者的快速通道资格认定，并于近期获得用于治疗晚期和转移性胆道癌的快速通道资格认定。In 2023, Phanes entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada) to study spevatamig in combination with pembrolizumab. Spevatamig is an innate immunity enhancer (I. 2023年，Phanes与默克公司（在美国和加拿大以外地区称为MSD）达成临床合作协议，共同研究spevatamig与帕博利珠单抗的联合疗法。Spevatamig是一种先天免疫增强剂（I.2 2E), an emerging class of IO agents. It has the potential to become the first I E），一类新兴的IO代理。它有潜力成为第一个I2 2E for a solid tumor indication and is combinable with various anti-cancer therapies. E 用于实体瘤适应症，并且可以与各种抗癌疗法联合使用。The multi-center Phase I/II clinical trial of spevatamig (NCT05482893), known as the TWINPEAK study, is currently evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of spevatamig in patients with advanced gastrointestinal cancers, including gastric, gastroesophageal Junction, pancreatic ductal, CRC or biliary tract adenocarcinomas. 斯佩瓦塔米格（spevatamig）的多中心I/II期临床试验（NCT05482893），即TWINPEAK研究，目前正在评估斯佩瓦塔米格在晚期胃肠道癌症患者中的安全性、耐受性、药代动力学和初步疗效，这些癌症包括胃癌、胃食管结合部癌、胰腺导管腺癌、结直肠癌（CRC）或胆道腺癌。The Phase I (CTR20241655) and Phase II (CTR20252758) clinical trials of spevatamig in China are currently recruiting patients with gastrointestinal cancers.. 斯佩瓦米格（spevatamig）在中国开展的I期（CTR20241655）和II期（CTR20252758）临床试验目前正在招募胃肠道癌症患者。ABOUT PHANES THERAPEUTICS 关于Phanes TherapeuticsPhanes Therapeutics, Inc. is a clinical-stage biotech company focused on innovative drug discovery and development in immuno-oncology (IO). Currently, it is conducting three Phase 2 clinical trials with spevatamig, peluntamig, and mavrostobart. Both spevatamig and peluntamig are first-in-class bispecific antibodies and have been granted orphan drug and Fast Track designations by the FDA.. Phanes Therapeutics, Inc. 是一家处于临床阶段的生物科技公司，专注于免疫肿瘤学（IO）领域的创新药物发现与开发。目前，该公司正在开展三项针对 spevatamig、peluntamig 和 mavrostobart 的二期临床试验。Speatvamig 和 peluntamig 均为同类首创的双特异性抗体，并已获得美国食品药品监督管理局（FDA）授予的孤儿药资格和快速通道认定。The company has built a strong pipeline by leveraging its proprietary technology platforms: PACbody®, SPECpair® and ATACCbody® to develop novel biologics that address high unmet medical needs in cancer. 该公司通过利用其专有技术平台——PACbody®、SPECpair® 和 ATACCbody®，构建了强大的产品管线，以开发满足癌症领域高度未竟医疗需求的新型生物药。For more information about Phanes Therapeutics, please visit 如需了解更多关于Phanes Therapeutics的信息，请访问www.phanesthera.com www.phanesthera.com. 。For business development or media inquiries, please contact 如有业务拓展或媒体问询，请联系[emailprotected] [email protected]or 或[emailprotected] [email protected], respectively. 分别。SOURCE Phanes Therapeutics, Inc. 来源：Phanes Therapeutics, Inc.21 二十一% %more press release views with 更多新闻稿浏览量，通过Request a Demo 申请演示
